| Adeola Aminat Adebayo, PMHNP | |
|
2716 Water Oak Dr, Grand Prairie, TX 75052-4448 | |
| (469) 740-2811 | |
| Not Available |
| Full Name | Adeola Aminat Adebayo |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Psychiatric/mental Health, Child & Family |
| Location | 2716 Water Oak Dr, Grand Prairie, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861048597 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0810X | Clinical Nurse Specialist - Psychiatric/mental Health, Child & Family | AP142733 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Adeola Aminat Adebayo, PMHNP 2716 Water Oak Dr, Grand Prairie, TX 75052-4448 Ph: (469) 740-2811 | Adeola Aminat Adebayo, PMHNP 2716 Water Oak Dr, Grand Prairie, TX 75052-4448 Ph: (469) 740-2811 |
News Archive
What you see is not always what you get. And that, researchers at The Rockefeller University have discovered, is a good thing.
University of Iowa scientists have discovered a new role for a protein that is mutated in Usher syndrome, one of the most common forms of deaf-blindness in humans. The findings, which were published Aug. 8 in Nature Neuroscience, may help explain why this mutation causes the most severe form of the condition.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 10,350,000 shares of its common stock, including 1,350,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offered by the Company. Net proceeds were approximately $53.3 million after deducting underwriting discounts and commissions, and estimated offering expenses. Canaccord Adams acted as sole book-running manager and Needham & Company, LLC acted as co-manager for the offering.
SuperGen Inc. has announced the presentation of data that describe how its proprietary CLIMB technology was used in lead development and design of small molecule Pim kinase inhibitors (Poster 845, Abstract 2655).
Treating metastatic non-small cell lung cancer patients with the immunotherapy drug pembrolizumab after they've completed locally ablative therapy – meaning all known sites of their cancer were either treated with surgery, radiation, or other definitive treatments – almost tripled the median progression-free survival compared to the historical average.
› Verified 9 days ago
Keara Rona' Johnson, DNP APRN FNP-BC Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 2775 N State Highway 360 Apt 1021, Grand Prairie, TX 75050 Phone: 316-516-4631 | |
Mr. Mbe Sylvester Tayourh, PMHNP Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 727 S Great Southwest Pkwy Apt 151, Grand Prairie, TX 75051 Phone: 202-706-0905 | |
Khalillah S Ali, NP Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 455 Gotland Dr, Grand Prairie, TX 75052 Phone: 469-831-3149 |